川芎嗪联合促肝细胞生长素治疗慢性乙型病毒性肝炎肝纤维化疗效观察.pdfVIP

维普资讯 · 药物与临床 · 川芎嗪联合促肝细胞生长素治疗慢性乙型病毒性肝炎肝纤维化疗效观察 郭 屏 ，王淑平，刘丹萍(湖北宜昌市第三人民医院，宜昌市 443003) 中图分类号 R975 ．5 文献标识码 A 文章编号 1001—0408(2007)08—0601—02 摘 要 目的：观察川芎嗪联合促肝细胞生长素治疗慢性乙型病毒性肝炎肝纤维化的临床疗效。方法：将 169例伴血清肝纤维化指 标异常的慢性乙型病毒性肝炎患者随机分为治疗组与对照组，前者给予川芎嗪联合促肝细胞生长素治疗，后者给予复方丹参治疗， 2组疗程均为3mo。结果：与治疗前比较，治疗组治疗后血清肝纤维化指标明显下降(P0．01)；与对照组治疗后比较，有非常显著 性差异 (P0．01)。治疗组与对照组总有效率分别为87．64％、70．00％ (P0．05)；半年随访，治疗组与对照组总有效率分别为 81．54％、67．44％(P0．05)。结论：川芎嗪联合促肝细胞生长素有较好的抗肝纤维化和改善肝功能作用。 关键词 慢性乙型病毒性肝炎；肝纤维化；Jl1芎嗪；促肝细胞生长素 ObservationofTherapeuticEffectsofLigustrazineCombinedwithPHGF intheTreatmentofChronicType B HepatitiswithHepaticFibrosis GUO Ping，WANG Shuping，LIU Danping(YichangThirdPeople’sHospitalofHubeiProvince，Yichang 443003，China) ABSTRACT OBJECTIVE：Toobservethetherapeuticeffectsofligustrazinehydrochlorideusedincombinationwithhepa— tocytegrowth——promotingfactor(PHGF)intreatingchronichepatitisBwithhepaticfibrosis．METHODS：169casesofchronic hepatitisBwithhepaticfibrosiswererandomly dividedintotwogroups：treatmentgroup andcontrolgroup．Fhetreatment groupwastreatedwithligustrazineandPHGFwhilethecontrolgroupwastreatedonlywithcompounddanshen，eachfora treatmentcourseofthreemonths．RESULTS：Inthetreatmentgrouptheserologicparametersofhepaticfibrosisdeclinedsig— nificantlyaftertreatment(P0．01)．Thereweresignificantdifferencescomparedwiththecontrolgroup(P0．01)．Theover— allefficacyratesinthetreatmentgroupandthecontrolgroupwere87．64％ and70．00％(P0．05)respectively．Attheendof sixmonthswithouttreatment．theoverallefficacyratesinthetwogroupswere81．54％and67．44％(P0．05)respectively． CONCLUS10N ：LigustrazinecombinedwithPHGF couldresisthepaticfibrosisandobviouslyimprovethehepaticfunctionin chronictypeBhepatitispatients． KEY W ORDS ChronichepatitisB；Hepaticfibrosis；Ligustrazinehydrochloride；Hepatocytegrowth—promotingfactor 在慢性乙型病毒性肝炎 (ChronichepatitisB，CHB)中， 治疗组给予盐酸川芎嗪注射液 120